BioWorld

Sep. 14, 2007

View Archived Issues

Isis Gets $45M Up Front In Deal With Ortho On Diabetes Drugs

Four months after licensing a preclinical, second-generation antisense drug for high cholesterol to Bristol-Myers Squibb Co. in a deal worth up to $192 million, Isis Pharmaceuticals Inc. is at it again. (BioWorld Today) Read More

Genmab's 'Turnaround' Year Includes More Cancer Focus

Read More

More Is More For Receptor Tyrosine Kinase Inhibitors

Read More

PTC Gets $20M Investment From Celgene For Oncology Targets

Read More

Cell Therapy Company Aldagen Adds $9M To Series C Financing

Read More

Other News To Note

Read More

Clinic Roundup

Read More